Ravulizumab




Ravulizumab Overview

Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).[1][2] In paroxysmal nocturnal hemoglobinuria, proteins known as the 'complement system', which is part of the immune system, become overactive because of a g...

Read more Ravulizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ravulizumab

Recent Ravulizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ravulizumab
  • Injection: 300mg/30ml(10mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Ravulizumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 27 September 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA